NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier

NeOnc Technologies (NASDAQ: NTHI) is advancing NEO100, an intranasal-delivered therapy for IDH1-mutant gliomas, following promising Phase 2a results showing 48.9% six-month progression-free survival versus a 20% benchmark with no major toxicities. The company plans to seek FDA guidance on a registrational pathway, with potential broader implications for nose-to-brain drug delivery technology.